Eterna Therapeutics Inc. (ERNA)
NASDAQ · Healthcare
Eterna Therapeutics Inc. EBITDA 2010–2024
Eterna Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2010 to 2024. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Eterna Therapeutics Inc. ebitda for the quarter ending September 30, 2024 was -2.2 M, a 8.95% increase year-over-year.
- Eterna Therapeutics Inc. ebitda for the twelve months ending September 30, 2024 was -18.0 M, a 250.68% increase year-over-year.
- Eterna Therapeutics Inc. annual ebitda for 2024 was -15.5 M, a 26.20% decrease from 2023.
- Eterna Therapeutics Inc. annual ebitda for 2023 was -21.1 M, a 36.32% decrease from 2022.
- Eterna Therapeutics Inc. annual ebitda for 2022 was -33.1 M, a 362.32% increase from 2020.
- Eterna Therapeutics Inc. annual ebitda for 2020 was -7.2 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Eterna Therapeutics Inc. EBITDA — FAQ
Eterna Therapeutics Inc. (ERNA) ebitda over the last 14 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see ERNA's ebitda history?
The chart and table above show Eterna Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.